WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York:
Key Points:
- WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York:
Jefferies Global Healthcare Conference: Formal Presentation on June 5, 2024 at 9:30 am ET
To access the live webcast of the presentation, please visit: https://investor.arbutusbio.com/events-presentations .
- An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
HBsAg,
Abstract (summary),
EASL,
Poster,
HBV,
Congress,
CHB,
Abstract,
Virology,
CFBV,
Vaccine The study remains ongoing and additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data for a subset of study subjects will be presented.
Key Points:
- The study remains ongoing and additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data for a subset of study subjects will be presented.
- Title: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone.
- Abstracts are available on the EASL Congress 2024 website at https://www.easlcongress.eu/ .
- The posters are expected to be made available to conference attendees at the start of the meeting on June 5, 2024.
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
Key Points:
- WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET
H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET
To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations .
- An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024.
Key Points:
- WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024.
- The schedule for the press release and conference call/webcast are as follows:
To dial-in for the conference call by phone, please register using the following link: Registration Link .
- A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com .
- An archived webcast will be available on the Arbutus website after the event.
Plaintiff,
Patent,
District court,
COVID-19,
CFBV,
Arbutus,
Sale,
Messenger,
Moderna,
Virology,
Interim,
Court,
LNP 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
Key Points:
- 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
- The following summarizes the Court’s Opinion:
The Court agreed with Plaintiffs’ position that the claimed molar percentage (mol.
- %) ranges can be met by any particle and is not limited to “finished” particles that are not subjected to further process steps.
- “We are pleased with how the Court construed the disputed claim terms,” said Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus Biopharma.
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
Key Points:
- WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
Barclays 26th Annual Global Healthcare Conference: Formal Presentation on March 12, 2024 at 2:05 pm ET
Jefferies Biotech on the Bay Summit: March 13, 2024
To access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference please visit: https://investor.arbutusbio.com/events-presentations .
- An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
Retrieved on:
Thursday, February 29, 2024
LNP,
HBV,
Court,
PD,
Research,
Virology,
Expert witness,
CFBV,
AASLD,
Construction,
Nivolumab,
Investment,
Arbutus,
HBsAg,
EASL,
Vaccine,
Interim,
Safety,
COVID-19,
Pharmacokinetics,
Roivant Sciences,
Patient,
Clinical trial,
Congress,
RNA interference,
DNA,
Pharmaceutical industry Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
Key Points:
- Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
- Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
- Arbutus is advancing AB-101 into part two of this clinical trial which involves dosing healthy subjects with multiple-ascending doses of AB-101.
- Roivant Sciences Ltd. owned approximately 23% of the Company’s outstanding common shares as of December 31, 2023.
Retrieved on:
Thursday, February 15, 2024
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.
Key Points:
- WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.
- The schedule for the press release and conference call/webcast are as follows:
Q4 and Year End 2023 Press Release:
Q4 and Year End 2023 Conference Call/Webcast:
To dial-in for the conference call by phone, please register using the following link: Registration Link .
- A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com .
- An archived webcast will be available on the Arbutus website after the event.
LNP,
RNA interference,
AASLD,
Virology,
HBV,
Vaccine,
Court,
Nivolumab,
Congress,
Clinical trial,
Pharmacokinetics,
PD,
Expert witness,
Arbutus,
COVID-19,
EASL,
CFBV,
Interim,
Investment,
Patient,
Safety,
HBsAg,
PD-L1,
Pharmaceutical industry Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
Key Points:
- Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
- Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
- Arbutus expects to report preliminary data from the healthy subject portion of this clinical trial, including target engagement and receptor occupancy data, in the first half of 2024.
- With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024.
Retrieved on:
Thursday, November 9, 2023
Group 3,
Hepatology,
Safety,
Immune system,
Thyroiditis,
RNA interference,
AASLD,
Risk,
MVA,
NUC,
Patient,
HBV,
Clinical trial,
Non-cirrhotic portal fibrosis,
Liver,
SOC,
Autoimmune thyroiditis,
CHB,
Cancer,
Nivolumab,
Hepatitis,
Group 2,
Autoimmunity,
Thyroid disease,
Șaeș,
Vaccine,
Pharmaceutical industry,
HBsAg Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
Key Points:
- Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
- Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
- Preliminary immunology data suggests HBV-specific T cell IFN-γ production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
- Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.
